Aspire Biopharma Holdings Inc (ASBP)

Feb 12, 2026

Aspire Biopharma secures up to $21M in convertible preferred stock financing - MSN

Feb 12, 2026

Feb 12, 2026

Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity - Worcester Telegram

Feb 12, 2026

Feb 12, 2026

Aspire Biopharma Announces Private Placement to Strengthen Finances - TipRanks

Feb 12, 2026

Feb 12, 2026

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - BlueRidgeNow.com

Feb 12, 2026

Feb 12, 2026

Aspire Biopharma Holdings Signs Multiple Material Agreements - TradingView

Feb 12, 2026

Feb 12, 2026

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R)) - ACCESS Newswire

Feb 12, 2026

Feb 12, 2026

New Zofran-style powder aims to bring IV-speed nausea relief at home - Stock Titan

Feb 12, 2026

Feb 11, 2026

Major Financial Concerns Loom as Aspire Biopharma Troubles Deepen - StocksToTrade

Feb 11, 2026

Feb 11, 2026

Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements - ACCESS Newswire

Feb 11, 2026

Feb 11, 2026

$21M cash boost aims to keep Aspire Biopharma on Nasdaq - Stock Titan

Feb 11, 2026

Feb 11, 2026

Aspire Biopharma Announces Reverse Stock Split - SouthCoastToday.com

Feb 11, 2026

Feb 10, 2026

Aspire Biopharma regains Nasdaq minimum bid price compliance By Investing.com - Investing.com Nigeria

Feb 10, 2026

Feb 10, 2026

Aspire Biopharma Provides Q3 2025 Business Update - Corpus Christi Caller-Times

Feb 10, 2026

Feb 10, 2026

Aspire Biopharma regains Nasdaq minimum bid price compliance - MSN

Feb 10, 2026

Feb 10, 2026

Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - itemonline.com

Feb 10, 2026

Feb 10, 2026

ASBP Stock Price, Forecast & Analysis | ASPIRE BIOPHARMA HOLDINGS IN (NASDAQ:ASBP) - ChartMill

Feb 10, 2026

Feb 06, 2026

Aspire Biopharma Holdings files for Series A convertible preferred stock on Nasdaq By Investing.com - Investing.com Nigeria

Feb 06, 2026

Feb 06, 2026

Aspire Biopharma Holdings files for Series A convertible preferred stock on Nasdaq - Investing.com Nigeria

Feb 06, 2026

Feb 05, 2026

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

Feb 05, 2026

Feb 05, 2026

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit - accessnewswire.com

Feb 05, 2026

Feb 05, 2026

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member - DelmarvaNow.com

Feb 05, 2026

Feb 04, 2026

Aspire Biopharma’s Buzz Bomb partners with Blue Shark Beverages - Yahoo Finance

Feb 04, 2026

Feb 04, 2026

Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA) - The Times-Mail

Feb 04, 2026

Feb 03, 2026

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution - Finviz

Feb 03, 2026

Feb 01, 2026

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of AlprazolamGeneric Xanax(R)for Rapid Anxiety Relief - The Clarion-Ledger

Feb 01, 2026

Feb 01, 2026

ASBPWAspire Biopharma Holdings Inc Latest Stock News & Market Updates - stocktitan.net

Feb 01, 2026

Jan 31, 2026

Aspire Biopharma Holdings raises $2 million through debenture sale By Investing.com - Investing.com Nigeria

Jan 31, 2026